StockData
Korro Bio, Inc. logo

Korro Bio, Inc. (KRRO) stock

KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$12.32−0.39 (-3.07%)

Close on Nov 17, 2026Market cap $181.42MP/E –Yield –

Korro Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Korro Bio's revenue for the twelve months ending Jun 30, 2026 was $2.38M, down 62.1% year over year. For fiscal 2025 it was $6.39M, up 181.5% from the year before. The highest annual figure on record is $36.98M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.39M+181.5%
FY2024Dec 31, 2024$2.27M–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0-100.0%
FY2021Dec 31, 2021$14.07M-62.0%
FY2020Dec 31, 2020$36.98M+27.8%
FY2019Dec 31, 2019$28.95M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$1.29M-43.1%
Q3 FY2025Sep 30, 2025$1.09M–
Q2 FY2025Jun 30, 2025$1.46M–
Q1 FY2025Mar 31, 2025$2.55M–
Q4 FY2024Dec 31, 2024$2.27M–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0-100.0%
Q1 FY2022Mar 31, 2022$0-100.0%
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$0-100.0%
Q2 FY2021Jun 30, 2021$9.42M+10.5%
Q1 FY2021Mar 31, 2021$4.65M-36.0%
Q4 FY2020Dec 31, 2020$9.95M+111.3%
Q3 FY2020Sep 30, 2020$11.25M-53.6%
Q2 FY2020Jun 30, 2020$8.52M–
Q1 FY2020Mar 31, 2020$7.26M–
Q4 FY2019Dec 31, 2019$4.71M–
Q3 FY2019Sep 30, 2019$24.24M–

More Korro Bio figures

See a number that looks wrong?